Screener
Syndax Pharmaceuticals SNDX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Syndax Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
FAQ
- What is Syndax Pharmaceuticals's debt-to-equity?
- Syndax Pharmaceuticals (SNDX) reported debt-to-equity of 8.4× in Q1 2026.
- How has Syndax Pharmaceuticals's debt-to-equity changed year-over-year?
- Syndax Pharmaceuticals's debt-to-equity increased by 438.6% year-over-year, from 1.6× to 8.4×.
- What is the long-term trend for Syndax Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's debt-to-equity has grown at a 402.4% compound annual growth rate (CAGR), from 0× to 5.4×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Syndax Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude